Price
CHART BY
Frequently asked questions
What is Vertex Pharms's market capitalization?
The market capitalization of Vertex Pharms is $138.98B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Vertex Pharms's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Vertex Pharms is 31.90. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Vertex Pharms?
Vertex Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $17.19. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Vertex Pharms's stock?
Currently, 33 analysts cover Vertex Pharms's stock, with a consensus target price of $574.32. Analyst ratings provide insights into the stock's expected performance.
What is Vertex Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Vertex Pharms reported a revenue of $12.70B.
What is the EBITDA for Vertex Pharms?
Vertex Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $5.24B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Vertex Pharms?
Vertex Pharms has a free cash flow of $3.80B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Vertex Pharms have, and what sector and industry does it belong to?
Vertex Pharms employs approximately 6,400 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Vertex Pharms's shares?
The free float of Vertex Pharms is 252.89M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $138.98B
- EPS (TTM)
- $17.19
- Free Float
- 252.89M
- P/E ratio (TTM)
- 31.90
- Revenue (TTM)
- $12.70B
- EBITDA (TTM)
- $5.24B
- Free Cashflow (TTM)
- $3.80B
Pricing
- 1D span
- $544.51$558.27
- 52W span
- $374.57$560.25
Analyst Ratings
The price target is $574.32 and the stock is covered by 33 analysts.
Buy
25
Hold
6
Sell
2
Information
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
- Employees
- 6,400
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- VRTX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet